Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Herpetic Keratitis Market: By Treatment, By Disease Type, By Route of Administration By End Users and Geography
Herpetic Keratitis Market was valued at US$ 4,130 Million in 2023 and is poised to grow at a CAGR of 6.1% over 2024-2030. Herpetic keratitis is a form of keratitis caused by recurrent herpes simplex virus infection in the cornea, which begins with infection of the epithelial cells on the surface of the eye and retrograde infection of nerves serving the cornea and is characterized by swelling of the conjunctiva and eyelids. Based on the treatment type, the anti-viral segment is anticipated to dominate the herpetic keratitis market share over the forecast period. According to the World Health Organization, nearly 3.7 billion people under the age of 50 years have herpes simplex virus type 1 infection, and around 491 million people aged 15 to 49 years have herpes simplex virus type 2 infection. The increasing prevalence of chronic diseases, rapid advancements in the healthcare sector, and high adoption of techniques are the major herpetic keratitis market growth drivers, while the high cost of treatment could hinder the growth of the market. The increasing rate of mergers and acquisitions will act as an opportunity for geographical expansion of the market.
Study Period
2024-2030Base Year
2023CAGR
6.1%Largest Market
North AmericaFastest Growing Market
Asia Pacific
The rising focus on drug development, increasing demand for precision medicine, high adoption of home care settings, point-of-care diagnostics, and increasing investments in research and development activities are expected to drive the market revenue growth during the forecast period. For instance, in 2019 a randomized trial was conducted using topical corticosteroid in addition to oral antivirals for HSV keratitis recurrence prevention. Moreover, approved drugs such as Famciclovir, Valacyclovir, Acyclovir, and other drugs are being used in the treatment of HSV infection. However, the challenges associated with the diagnosis of the disease could act as a restraining factor.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market CAGR |
6.1% |
By Treatment |
|
By Disease Type |
|
By Route of Administration |
|
By End User |
|
Download Free Sample Report
The Herpetic Keratitis market was valued at US$ 4,130 million in 2022 and is expected to grow at a 6.1% CAGR over the forecast period 2023 – 2029.
The increasing rate of mergers and acquisitions is the key opportunity for the Herpetic Keratitis market.
The increasing prevalence of skin conditions, rapid advancements in the healthcare sector, and high adoption of techniques are the growth drivers in the Herpetic Keratitis market.
Bausch & Lomb Incorporated, Vectans Pharma, GlaxoSmithKline plc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Jubilant Cadista, Mylan N.V., and Blistex are a few companies operating in the Herpetic Keratitis market.
1.Executive Summary |
2.Global Herpetic Keratitis Market Introduction |
2.1.Global Herpetic Keratitis Market - Taxonomy |
2.2.Global Herpetic Keratitis Market - Definitions |
2.2.1.Treatment |
2.2.2.Disease Type |
2.2.3.Route of Administration |
2.2.4.End User |
2.2.5.Region |
3.Global Herpetic Keratitis Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Herpetic Keratitis Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Herpetic Keratitis Market By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Topical Steroids |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Anti-viral drugs |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Interferons |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Others |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6.Global Herpetic Keratitis Market By Disease Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Epithelial |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Disciform |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Neurotrophic |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Necrotizing |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7.Global Herpetic Keratitis Market By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Oral |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Topical |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
8.Global Herpetic Keratitis Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. Hospitals |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Specialty Clinics |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Homecare |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Others |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
9.Global Herpetic Keratitis Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia Pacific (APAC) |
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Middle East and Africa (MEA) |
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Latin America |
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
10.North America Herpetic Keratitis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Topical Steroids |
10.1.2.Anti-viral drugs |
10.1.3.Interferons |
10.1.4.Others |
10.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Epithelial |
10.2.2.Disciform |
10.2.3.Neurotrophic |
10.2.4.Necrotizing |
10.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Oral |
10.3.2.Topical |
10.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Hospitals |
10.4.2.Specialty Clinics |
10.4.3.Homecare |
10.4.4.Others |
10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1.United States of America (USA) |
10.5.2.Canada |
11.Europe Herpetic Keratitis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Topical Steroids |
11.1.2.Anti-viral drugs |
11.1.3.Interferons |
11.1.4.Others |
11.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Epithelial |
11.2.2.Disciform |
11.2.3.Neurotrophic |
11.2.4.Necrotizing |
11.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Oral |
11.3.2.Topical |
11.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.Hospitals |
11.4.2.Specialty Clinics |
11.4.3.Homecare |
11.4.4.Others |
11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1.Germany |
11.5.2.France |
11.5.3.Italy |
11.5.4.United Kingdom (UK) |
11.5.5.Spain |
12.Asia Pacific (APAC) Herpetic Keratitis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Topical Steroids |
12.1.2.Anti-viral drugs |
12.1.3.Interferons |
12.1.4.Others |
12.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Epithelial |
12.2.2.Disciform |
12.2.3.Neurotrophic |
12.2.4.Necrotizing |
12.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Oral |
12.3.2.Topical |
12.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.Hospitals |
12.4.2.Specialty Clinics |
12.4.3.Homecare |
12.4.4.Others |
12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1.China |
12.5.2.India |
12.5.3.Australia and New Zealand (ANZ) |
12.5.4.Japan |
12.5.5.Rest of APAC |
13.Middle East and Africa (MEA) Herpetic Keratitis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Topical Steroids |
13.1.2.Anti-viral drugs |
13.1.3.Interferons |
13.1.4.Others |
13.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Epithelial |
13.2.2.Disciform |
13.2.3.Neurotrophic |
13.2.4.Necrotizing |
13.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Oral |
13.3.2.Topical |
13.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Hospitals |
13.4.2.Specialty Clinics |
13.4.3.Homecare |
13.4.4.Others |
13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1.GCC Countries |
13.5.2.South Africa |
13.5.3.Rest of MEA |
14.Latin America Herpetic Keratitis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
14.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.1.1.Topical Steroids |
14.1.2.Anti-viral drugs |
14.1.3.Interferons |
14.1.4.Others |
14.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.2.1.Epithelial |
14.2.2.Disciform |
14.2.3.Neurotrophic |
14.2.4.Necrotizing |
14.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.3.1.Oral |
14.3.2.Topical |
14.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.4.1.Hospitals |
14.4.2.Specialty Clinics |
14.4.3.Homecare |
14.4.4.Others |
14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.5.1.Brazil |
14.5.2.Mexico |
14.5.3.Rest of LA |
15. Competition Landscape |
15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
15.2.1.Bausch & Lomb Incorporated |
15.2.2.Vectans Pharma |
15.2.3.GlaxoSmithKline plc. |
15.2.4.Aurobindo Pharma Ltd. |
15.2.5.Reddy's Laboratories Ltd. |
15.2.6.Cipla Ltd. |
15.2.7.Jubilant Cadista |
15.2.8.Mylan N.V. |
15.2.9.Blistex |
16. Research Methodology |
17. Appendix and Abbreviations |
Key Market Players